There is described a method for increasing the maximal tolerated dose and thusthe efficacy of an acetyl cholinees-terase inhibitor (AChEI) in a patient suffering from an Alzheimer typedementia by decreasing concomitant adverse effects byad-ministration of said AChEI in combination with a non-selective, peripheralanticholinergic agent, whereby an enhanced acetylcholine esterase inhibition in the CNS of said patient is achieved andalleviation of the symptoms of Alzheimer type dementia insaid patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for thepreparation of a pharmaceutical composition for increasing the maximaltolerated dose and thus the efficacy of an acetyl cholineesterase inhibitor (AChEI) in a patient suffering from an Alzheimer typedementia and pharmaceutical compositions comprising anon-selective peripheral anticholinergic agent of formula II as illustrated inthe description and an acetylcholine esterase inhibitorare also described.
